受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 2022年，九天中创虚假确认与江西米赞科技有限公司（以下简称江西米赞）的大连智云自动化装备股份 有限公司销售收入5，973.45万元、利润2，411.23万元，分别占智云股份同期披露营业收入、利润总额 绝对值的13.27%、7.09%。具体情况如下： 2022年4月至10月，九天中创为确认上述收入，分多笔向冠威科技（武汉）有限公司（以下简称武汉冠 威）、深圳市青睿自动化科技有限公司、东莞市鑫明科技有限公司三家供应商转款共计6820万元。三家 供应商收到款项当日或隔几日向江西米赞转款6770万元（武汉冠威截留50万元）。江西米赞收到款项当 日或隔几日向九天中创转款6750万元（江西米赞截留20万元）。上述6750万元销售收入（含增值税 776.55万元）在九天中创、三家供应商与江西米赞间形成明显资金循环，无对应真实销售业务。九天中 创虚假确认销售收入，导致智云股份2022年年度报告存在虚假记载。 专门从事股票索赔法律事务的上海久诚律师事务所主任许峰律师认为，根据前期投资者胜诉判决，在 2023年4月28日到 ...

一、鼎信通讯未及时披露生产经营的外部条件发生重大变化 鼎信通讯于2024年2月27日知悉国家电网自2024年2月18日起对公司全部采购品类启动招标采购"熔断机 制"，并对公司涉嫌违规事项启动调查，熔断期间暂停公司全部产品、服务中标资格。"熔断机制"对公 司中标金额产生重大影响， 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 上海久诚律师事务所股票索赔律师许峰提示，鼎信通讯（维权）（603421）虚假陈述引发的投资者索赔 案已有投资者胜诉先例，目前还在诉讼时效内，受损投资者还可起诉。（许峰律师专栏） 许峰律师提示，部分投资者发起的虚假陈述索赔诉讼已获得终审胜诉判决。许峰律师团队目前还在继续 推进后续案件的立案工作，还在继续接受其他投资者的索赔委托。 此前2024年5月9日，鼎信通讯公告收到青岛证监局《行政处罚决定书》。经查明，鼎信通讯存在以下违 法事实： 国家电网中标产品金额占公司营业收入比重较高，构成公司生产经营的外部条件发生重大变化，该事项 ...

Core Viewpoint - The article discusses ongoing legal actions against Zhitong Electronics (证通电子) due to false statements leading to investor claims, with the Shenzhen Intermediate Court having accepted the case for further proceedings [1][2][3]. Group 1: Legal Proceedings - The investor claims against Zhitong Electronics are being represented by attorney Xu Feng from Shanghai Jucheng Law Firm, who is actively pursuing further cases and accepting additional claims from investors [1][2]. - The Shenzhen Intermediate Court has officially accepted the case related to the false statements made by Zhitong Electronics, and the legal team is awaiting the next steps from the court [1][2]. Group 2: Financial Misconduct - Zhitong Electronics was found to have engaged in fraudulent activities through its subsidiary, Guangzhou Yunshuo, which involved fictitious procurement and sales contracts that lacked commercial substance [4][5]. - In 2017, Guangzhou Yunshuo inflated its revenue by approximately 17.64 million yuan, with a corresponding profit increase of about 5.08 million yuan, which represented 13.78% of the total disclosed profit for that year [2][4]. - In 2019, the inflated revenue was around 6.89 million yuan, leading to a profit increase of approximately 840,040.83 yuan, accounting for 12.52% of the total disclosed profit for that year [2][4]. Group 3: Investor Compensation - Investors who purchased Zhitong Electronics shares between April 15, 2021, and April 30, 2024, or between April 24, 2018, and May 30, 2024, are eligible to file claims for compensation [5]. - The law firm has a history of successfully representing investors in similar cases, with many achieving settlements or favorable outcomes [5].

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 上海久诚律师事务所投资者索赔律师许峰提示，奥联电子（维权）（300585）虚假陈述投资者索赔案还 在起诉时效内，如果投资者因此受损，目前还可发起索赔。（许峰律师专栏） 许峰律师代理的奥联电子投资者索赔案中部分案件已经获赔到位，目前律师团队还在继续推进后续案件 的立案工作，还在继续接受其他投资者的索赔委托。 2024年4月7日晚，奥联电子公告收到证监会《行政处罚决定书》，经查，奥联电子等违法事实如下： 奥联电子披露的胥明军在钙钛矿领域的业绩存在误导性陈述。 （一）关于胥明军在钙钛矿行业主要业绩的内容存在误导性陈述 （本文由上海久诚律师事务所主任许峰律师供稿，不代表新浪财经立场。许峰律师，2008年起律师执 业，执业服务范围涉及虚假陈述、内幕交易、操纵市场等证券欺诈领域索赔代理。十几年来已代理近两 百只股票的投资者胜诉或调解获赔，同期还在代理诉讼时效内 ...

Group 1 - The core issue involves the manipulation of stock prices of Hengrun Co., Ltd. (603985), leading to investor claims against the company [1][2] - The China Securities Regulatory Commission (CSRC) has imposed administrative penalties on key individuals involved in the manipulation, including the second-largest shareholder and the chairman [1][3] - Between July 29 and November 8, 2023, the stock price of Hengrun Co. increased by 96.65%, significantly outperforming the Shanghai Composite Index, which fell by 6.86% during the same period [1][2] Group 2 - The manipulation involved the use of multiple securities accounts to maintain the stock price, with a total of 15,754,477 shares bought during the price decline, amounting to approximately 457.25 million yuan [2] - The CSRC found that from 2020 to 2023, Dongfang Group engaged in fraudulent activities that inflated reported revenues and costs, with significant discrepancies in financial reporting [3][4] - The inflated revenues for Dongfang Group were reported as 3.90 billion yuan, 4.87 billion yuan, 6.54 billion yuan, and 824.80 million yuan for the years 2020 to 2023, respectively [3]

Group 1 - The core issue involves investor claims against Aolian Electronics (300585) due to false statements, with ongoing legal actions being pursued by attorney Xu Feng [1][2] - Aolian Electronics received an administrative penalty from the China Securities Regulatory Commission (CSRC) for misleading statements regarding its performance in the perovskite sector, leading to a significant stock price drop of 29.92% over two trading days [1] - The stock price decline of Aolian Electronics was notably higher than the broader market, with a deviation of 28.76 percentage points from the ChiNext Index during the same period [1] Group 2 - Attorney Xu Feng indicates that investors who purchased Aolian Electronics shares between December 12, 2022, and February 21, 2023, may still initiate claims, as the statute of limitations is nearing its end [2] - The law firm is also handling claims for investors of Puli Pharmaceutical (300630), with some cases already in court and awaiting further court arrangements [2] - Puli Pharmaceutical was found to have inflated its revenue and profits through fictitious sales from 2021 to 2022, with significant overstatements in both years [3] Group 3 - Investors who bought Puli Pharmaceutical shares between April 26, 2022, and April 17, 2024, are also eligible to file claims, as per attorney Xu Feng's guidance [4] - The law firm has a history of successfully representing investors in securities fraud cases, with numerous claims currently in progress [4]

Core Viewpoint - The article discusses ongoing legal actions against Yangzi New Materials and Haiyue Energy for false statements and significant omissions in their financial disclosures, highlighting potential compensation opportunities for affected investors [1][3][4]. Group 1: Yangzi New Materials - Yangzi New Materials is facing legal claims from investors due to false statements and significant omissions in its annual reports, particularly regarding related party transactions and financial misreporting [1][3]. - The company failed to disclose substantial related party fund occupation, with amounts reaching approximately 197.65 million yuan in 2018 and 363.31 million yuan in 2019 [1]. - In 2020, Yangzi New Materials inflated its revenue by approximately 137.10 million yuan, accounting for about 11% of its reported revenue for that year [3]. Group 2: Haiyue Energy - Haiyue Energy is also under scrutiny for failing to disclose non-operating fund occupation by its controlling shareholder and for misreporting its financial results [4][5]. - The company acknowledged accounting errors that led to an overstatement of revenue and costs by approximately 302.08 million yuan in its 2022 semi-annual report, which represented 49.33% of its reported revenue [5]. - Legal actions are being pursued for investors who bought Haiyue Energy shares during specific periods, with opportunities for compensation still available [6].

Core Viewpoint - A class action securities lawsuit has been filed against Semler Scientific, Inc. for alleged securities fraud affecting investors between March 10, 2021, and April 15, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Semler Scientific failed to disclose a significant investigation by the U.S. Department of Justice regarding violations of the False Claims Act, while discussing potential violations in hypothetical terms [3]. - The complaint alleges that the public statements made by the defendants were materially false and misleading during the relevant time period [3]. Group 2: Investor Information - Investors who suffered losses in Semler Scientific during the specified timeframe have until October 28, 2025, to request to be appointed as lead plaintiff [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [5].

Core Points - The ongoing investor compensation cases against Guanghui Logistics (600603) and Gome Communication (600898) due to false statements are being actively pursued [1][2] - Guanghui Logistics has been found to have inflated its revenue, costs, and profits through fraudulent practices, significantly affecting its financial reports for 2022 and the first half of 2023 [1] - Gome Communication has also been implicated in false reporting, with its 2020 annual report showing inflated revenue and costs, as well as fraudulent stock issuance [3][4] Guanghui Logistics (600603) - Guanghui Logistics has received an administrative penalty from the China Securities Regulatory Commission (CSRC) for falsifying delivery documents to prematurely recognize real estate revenue [1] - The company inflated its 2022 revenue by approximately 2.89 billion yuan, which accounted for 57.65% of the reported revenue, and inflated its profit by about 622 million yuan, representing 78.52% of the reported profit [1] - For the first half of 2023, the company inflated its revenue by approximately 265 million yuan, which was 19.23% of the reported revenue, and inflated its profit by about 55 million yuan, accounting for 15.98% of the reported profit [1] Gome Communication (600898) - Gome Communication has been found to have false entries in its 2020 annual report, inflating revenue by approximately 57.82 million yuan and costs by about 57.46 million yuan, which represented 61.53% and 62.18% of the respective totals [3] - The company’s 2020 non-public stock issuance has been classified as fraudulent [3] - The 2021 annual report also contained false entries, with a net profit overstatement of approximately 1.96 million yuan, which was 38.35% of the reported net profit [3][4]

Core Viewpoint - The company Shenqi Pharmaceutical has faced regulatory scrutiny due to financial misconduct, leading to a significant drop in its stock price and raising concerns about its future performance [2][3]. Group 1: Regulatory Issues - Shenqi Pharmaceutical received an administrative regulatory decision from the Shanghai Securities Regulatory Bureau, citing violations related to the misappropriation of sales expenses amounting to 44.838 million yuan through fictitious accounts [2]. - The company has been ordered to rectify its accounting practices, and three executives, including the chairman, received warning letters [2]. - The company claims that the regulatory measures will not affect its normal operations and is currently preparing a rectification report [2]. Group 2: Financial Performance - The company reported a net profit of less than 100 million yuan in recent years, a decline from levels seen before 2019, with revenue continuously decreasing since its peak in 2022 [3][6]. - For the first half of 2025, the company is projected to have revenues of 961 million yuan and a net profit of 32.808 million yuan, representing year-on-year declines of 13.47% and 13.29%, respectively [10]. - The main business segments of the company are pharmaceutical manufacturing and commercial operations, contributing approximately 60% and 40% to revenue, respectively [6]. Group 3: Market Challenges - The company's product line includes older medications, which have faced declining sales due to various healthcare cost control policies, such as payment reforms and price adjustments [6]. - Specific products, such as the sodium cantharidate injections, have seen significant sales in the past but are now categorized closer to auxiliary medications, impacting overall revenue [6].